Skip to main content

Breadcrumb

  1. Home

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system

Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse

Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL

Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Page 86
  • Page 87
  • Page 88
  • Page 89
  • Page 90
  • …
  • Next page Next
  • Last page Last
Subscribe to